Literature DB >> 24446393

Analysis of new biomarkers for cholangiocarcinoma.

Masanao Miwa1, Gyokukou You, Hideaki Tanaka, Seigo Taniguchi, Takahiro Fujii, Kazuo Kamemura, Masafumi Suzaki, Takahiro Isono, Ikuo Tooyama, Masakazu Tanaka, Petcharin Srivatanakul, Chutiwan Viwatthanasittiphong, Suleeporn Sangrajrang, Thiravud Khuhaprema.   

Abstract

Cholangiocarcinoma is one of the most serious diseases in northeast Thailand, where its incidence is reported to be the highest in the world. We tried to develop a new method to detect cholangiocarcinoma in the early stages using serum proteins. We found that after fluorescent labeling of the sugar moiety of serum proteins, a new peak was identified, which might be a promising marker for cholangiocarcinoma.
© 2014 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Biliary tract cancer · Cholangiocarcinoma · Opisthorchis viverrini · Tumor marker

Mesh:

Substances:

Year:  2014        PMID: 24446393     DOI: 10.1002/jhbp.69

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  3 in total

Review 1.  Genetic and environmental determinants of risk for cholangiocarcinoma in Thailand.

Authors:  Masanao Miwa; Satoshi Honjo; Gyokukou You; Masakazu Tanaka; Kazuhiko Uchida; Petcharin Srivatanakul; Thiravud Khuhaprema; Watcharin Loilome; Anchalee Techasen; Chaisiri Wongkham; Temduang Limpaiboon; Puangrat Yongvanit; Sopit Wongkham
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

2.  Soluble TGFBI aggravates the malignancy of cholangiocarcinoma through activation of the ITGB1 dependent PPARγ signalling pathway.

Authors:  Jungwhoi Lee; Jungsul Lee; Woogwang Sim; Jae-Hoon Kim
Journal:  Cell Oncol (Dordr)       Date:  2022-03-31       Impact factor: 6.730

3.  Identification of Cholangiocarcinoma Associated with Hepatolithiasis via the Combination of miRNA and Ultrasound.

Authors:  Wei Jiang; Xiaofei Deng; Ting Zhu; Yuya Wei; Zhen Lei; Meimei Guo; Jiong Yang
Journal:  Cancer Manag Res       Date:  2020-03-12       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.